Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;5(1):29-33.
doi: 10.4103/0976-7800.127788.

First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates

Vishal R Tandon  1 , Sudhaa Sharma  2 , Shagun Mahajan  3 , Annil Mahajan  4 , Vijay Khajuria  1 , Zahid Gillani  1
Affiliations

First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates

Vishal R Tandon et al. J Midlife Health. 2014 Jan.

Abstract

Aim: The aim of the following study is to evaluate adherence and compliance of postmenopausal osteoporotic patients for different regimens of bisphosphonates (BP).

Materials and methods: A prospective observational randomized comparative 1 year study was undertaken to evaluate the adherence/compliance rates of most commonly prescribed daily alendronate (ALN), weekly risedronate (RIS) and monthly ibandronate (IBN) BP regimens.

Results: Nearly 40% was the 1 year adherence rate with BP and 41.33% of non-compliance. Whereas, 8.66% was interrupted compliance rate and 6% switched over to other anti-osteoporotic treatment. The three treatment arm did not vary significantly. However, numerically maximum adherence rate of 56% was recorded in monthly BP regimen followed by weekly (36%) and daily regimen (32%). Medication possession rate confirmed on a follow-up visit was maximum with monthly regimen as 84.61% followed by daily (62.5%) and weekly (61.11%) respectively. Average time in days for non-adherence was 48, 56 and 92 day with daily ALN, weekly RIS and monthly IBN regimen respectively. Age, mean age at menopause, demographical profile failed to influence the adherence. Concomitant treatment for co-morbid condition (57.14%), unawareness about osteoporosis (OP) (50%), cost of treatment (45.33%), belief that drugs is for their general disability (39.28%), physician's failure to stress the need and necessary calcium + vitamin D daily requirement (23.80%) each were the most prevalent factors responsible for non-adherence. Intolerance and adverse drug reactions were responsible for only 13.09% and 11.90% of non-adherence.

Conclusion: Treatment compliance is poor with daily ALN, weekly RIS and monthly IBN regimen along with calcium and vitamin D3 in Indian paramedical workers suffering OP.

Keywords: Adherence; alendronate; bisphosphonates; compliance; ibandronate; postmenopausal osteoporosis; risedronate.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Similar articles

See all similar articles

Cited by

References

    1. Genazzani AR, Gambacciani M, Schneider HP, Christiansen C. International Menopause Society Expert Workshop. Postmenopausal osteoporosis: Therapeutic options. Climacteric. 2005;8:99–109. - PubMed
    1. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17:25–54. - PubMed
    1. Delmas PD, Siris ES. NICE recommendations for the prevention of osteoporotic fractures in postmenopausal women. Bone. 2008;42:16–8. - PubMed
    1. Mendoza N, Sánchez-Borrego R, Villero J, Baró F, Calaf J, Cancelo MJ, et al. 2013 Up-date of the consensus statement of the Spanish Menopause Society on postmenopausal osteoporosis. Maturitas. 2013;76:99–107. - PubMed
    1. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23–57. - PMC - PubMed